Ziprasidone

From WikiMD's Wellness Encyclopedia

(Redirected from Geodon)

Ziprasidone


Ziprasidone is an antipsychotic medication used to treat schizophrenia and bipolar disorder. It belongs to the class of drugs known as atypical antipsychotics or second-generation antipsychotics. Ziprasidone works by altering the effects of chemicals in the brain, particularly serotonin and dopamine, which are thought to be involved in the pathology of psychotic disorders and mood disturbances.

Medical Uses[edit | edit source]

Ziprasidone is primarily indicated for the treatment of schizophrenia, a mental disorder characterized by distorted thinking, perceptions, emotions, and behavior. It is also used for the acute treatment of manic or mixed episodes associated with bipolar disorder. In some cases, ziprasidone may be prescribed off-label for other conditions as determined by a healthcare provider.

Mechanism of Action[edit | edit source]

The exact mechanism of action of ziprasidone is not fully understood. However, it is believed to exert its antipsychotic effects through a combination of dopamine type 2 (D2) and serotonin type 2 (5-HT2) receptor antagonism. Ziprasidone has a high affinity for serotonin receptors compared to dopamine receptors, which may contribute to its unique clinical profile. It also exhibits affinity for other neurotransmitter receptors, including histamine and adrenergic receptors, which may explain some of its side effects.

Pharmacokinetics[edit | edit source]

After oral administration, ziprasidone is well absorbed, with peak plasma concentrations occurring within 1 to 6 hours. Its bioavailability is significantly increased when taken with food. Ziprasidone is extensively metabolized in the liver, primarily through aldehyde oxidase and cytochrome P450 3A4 (CYP3A4). Its elimination half-life ranges from 2 to 5 hours, and it is excreted primarily in the urine and feces.

Side Effects[edit | edit source]

Common side effects of ziprasidone include dizziness, nausea, constipation, and somnolence. It may also cause orthostatic hypotension, leading to dizziness or fainting upon standing up too quickly. Unlike some other atypical antipsychotics, ziprasidone has a lower risk of weight gain and metabolic syndrome. However, it has been associated with a risk of QT interval prolongation, a type of heart rhythm disturbance, which necessitates caution in patients with certain cardiovascular conditions.

Contraindications[edit | edit source]

Ziprasidone is contraindicated in individuals with a known hypersensitivity to the drug or any of its components. It should not be used in patients with a history of QT interval prolongation, recent acute myocardial infarction, or uncompensated heart failure. Caution is advised when prescribing ziprasidone to patients with a history of seizures or conditions that could affect the metabolism or hemodynamic responses.

Interactions[edit | edit source]

Ziprasidone may interact with other medications that prolong the QT interval, increase the risk of arrhythmias, or affect its metabolism. These include certain antidepressants, antibiotics, and drugs that inhibit or induce CYP3A4. Patients should inform their healthcare provider of all medications they are taking to avoid potential drug interactions.

Conclusion[edit | edit source]

Ziprasidone is an effective medication for the treatment of schizophrenia and bipolar disorder, with a unique pharmacological profile that distinguishes it from other atypical antipsychotics. While it has a favorable side effect profile in terms of metabolic effects, its potential for causing QT interval prolongation requires careful patient selection and monitoring.

Ziprasidone Resources

Contributors: Prab R. Tumpati, MD